Developments BioPorto initiates patient enrollment in adult urine NGAL validation study BioPorto (CPH: BIOPOR) has announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to... September 17, 2026